Treatment of Myeloproliferative Neoplasms—Implications for a JAK2 Inhibitor Era Future Directions
MPN symptomology merits continued investigation. The detrimental impact of MPNs on quality of life and overall poor prognosis have resulted in further research into novel therapeutic agents capable of targeting more than palliative symptoms. The new class of JAK2
1. Dupriez B, Morel P, Demory JL, et al., Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system, Blood, 1996;88(3):1013–8.
2. Passamonti F, Rumi E, Pungolino E, et al., Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia, Am J Med, 2004;117(10):755–61.
3. Mesa RA, Silverstein MN, Jacobsen SJ, et al., Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995, Am J Hematol, 1999;61(1):10–5.
4. Tefferi A, Myelofibrosis with myeloid metaplasia, N Engl J Med, 2000;342(17):1255–65.
5. Mesa RA, Niblack J, Wadleigh M, et al., The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients, Cancer, 2007;109(1):68–76.
6. Mesa RA, Schwager S, Huang J, et al., Weight Loss, Splenomegaly, and Hypocholesterolemia in Myeloproliferative Neoplasms: Patterns and Relevance from the Pre JAK2 Inhibitor Era, Blood, 2009;114:3918, ASH Annual Meeting Abstracts, New Orleans, LA, December 7, 2009.
7. Mesa RA, How I treat symptomatic splenomegaly in patients with myelofibrosis, Blood, 2009;113:5394–400.
8. Varki A, Lottenberg R, Griffith R, et al., The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival, Medicine, 1983;62(6):353–71.
9. Mesa RA, Schwager S, Huang J, et al., Dynamics, and prognostic impact, of weight loss in primary myelofibrosis, Blood, 2008;112(11):5224.
10. Gilbert HS, Ginsberg H, Fagerstrom R, et al., Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity, Am J Med, 1981;71(4):595–602.
11. Mesa RA, Huang J, Schwager S, et al., Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative Patients, Blood, 2007;110(11):2548.
12. Kiss A, Telek B, Rak K, Hypocholesterolemia and other lipoprotein disorders in myelofibrosis, Orvosi Hetilap, 1994;135(48):2643–6.
13. Lofvenberg E, Wahlin A, Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea, Eur J Haematol, 1988;41(4):375–81.
14. Petti MC, Latagliata R, Spadea T, et al., Melphalan treatment in patients with myelofibrosis with myeloid metaplasia, Br J Haematol, 2002;116(3):576–81.
15. Manoharan A, Pitney WR, Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis, Scand J Haematol, 1984;33(5):453–9.
inhibitors appears efficacious in early clinical trials in reducing splenomegaly associated with disease as well as reducing cachexia and hypocholesterolemia. With a variety of JAK2 inhibitors beginning to enter clinical trials, there is potential for successful MPN symptom reduction, which may translate into improved quality of life for MPN patients. n
16. Barosi G, Elliot M A, Canepa L, et al., Thalidomide in myelofibrosis with myeloid metaplasia: a pooled analysis of individual patient data from five studies, Leukemia Lymphoma, 2002;43(12):2301–7.
17. Tefferi A, Cortes J, Verstovsek S, et al., Lenalidomide therapy in myelofibrosis with myeloid metaplasia, Blood, 2006;108:1158–64.
18. Tefferi A, Verstovsek S, Barosi G, et al., Pomalidomide therapy in anemic patients with myelofibrosis: results from a phase-2 randomized multicenter study, Blood, 2008;112(11):663.
19. Mesa RA, Steensma DP, Pardanani A, et al., A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia, Blood, 2003;101(7):2534–41.
20. Levy B, Vandris K, Adriano F, et al., Recombinant Interferon Alpha (rIFN{alpha}) May Retard Progression of Early Primary Myelofibrosis (PM) by Reducing Splenomegaly and by Changing Marrow Morphology, Blood, 2008;112(11):1758, ASH Annual Meeting Abstracts, San Francisco, CA, November 16, 2008.
21. Faoro LN, Tefferi A, Mesa RA, Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia, Eur J Haematol, 2005;74(2):117–20.
22. Quintás-Cardama A, Tong W, Kantarjian H, et al., A phase II study of 5-azacitidine for patients with primary and post essential thrombocythemia/polcythemia vera myelofibrosis, Leukemia, 2008;22:965–70.
23. Mesa RA, Verstovsek S, Rivera C, et al., 5-Azacitidine has limited therapeutic activity in myelofibrosis, Leukemia, 2009;23(1):180–2.
24. Danilov AV, Relias V, Feeney DM, et al., Decitabine is an effective treatment of idiopathic myelofibrosis, Br J Haematol, 2009;145(1):131–2.
25. Tefferi A, Barbui T, bcr/abl-negative, classic myeloproliferative neoplasms: diagnosis and treatment, Mayo Clin Proc, 2005;80(9):1220–32.
26. Mesa RA, Tefferi A, Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis, Exp Opin Emerg Drugs, 2009;14(3):471–9.
27. Mesa RA, New insights into the pathogenesis and treatment of chronic myeloproliferative disorders, Curr Opin Hematol, 2008;15(2):121–6.
28. Deeg HJ, Gooley TA, Flowers ME, et al., Allogeneic hematopoietic stem cell transplantation for myelofibrosis, Blood, 2003;102(12):3912–8.
29. Mesa RA, New drugs for the treatment of myelofibrosis, Curr Hematol Malignancy Rep, 2010;5(1):15–21.
30. Tefferi A, Kantarjian HM, Pardanani AD, et al., The clinical phenotype of myelofibrosis encompasses a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1/2, Blood, 2008;112(11):2804, ASH Annual Meeting Abstracts, San Francisco, CA, November 16, 2008.
31. Mesa RA, Verstovsek S, Kantarjian HM, et al., INCB018424, a selective JAK1/2 inhibitor, significantly improves the compromised nutritional status and frank cachexia in patients with myelofibrosis (MF), Blood, 2008;112(11):1760, ASH Annual Meeting Abstracts, San Francisco, CA, November 16, 2008.
32. Verstovsek S, Kantarjian H, Mesa RA, et al., Long-term follow up and optimized dosing regimen of INCB018424 in patients with myelofibrosis: durable clinical, functional and symptomatic responses with improved hematological safety, Blood, 2009;114(22):756, ASH Annual Meeting Abstracts, New Orleans, LA, December 7, 2009.
33. Verstovsek S, Passamonti F, Rambaldi A, et al., A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea, Blood, 2009;114(22):311, ASH Annual Meeting Abstracts, New Orleans, LA, December 7, 2009.
34. Verstovsek S, Odenike O, Scott B, et al., Phase I dose- escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis, Blood, 2009;114(22):3905, ASH Annual Meeting Abstracts, New Orleans, LA, December 7, 2009.
35. Pardanani AD, Gotlib JR, Jamieson CJ, et al., A phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden, Blood, 2009;114(22):755, ASH Annual Meeting Abstracts, New Orleans, LA, December 7, 2009.
36. Mascarenhas J, Wang X, Rodriguez A, et al., A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post-PV/ET MF), Blood, 2009;114(22):308, ASH Annual Meeting Abstracts, New Orleans, LA, December 7, 2009.
37. Vannucchi AM, Guglielmelli P, Gattoni E, et al., RAD001, an Inhibitor of mTOR, shows clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (PPV/PET MF), Blood, 2009;114(22):307, ASH Annual Meeting Abstracts, New Orleans, LA, December 7, 2009.
38. Hexner E, Goldberg JD, Prchal JT, et al., A multicenter, open label phase I/II study of CEP701 (lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the myeloproliferative disorders research consortium (MPD-RC), Blood, 2009;114(22):754, ASH Annual Meeting Abstracts, New Orleans, LA, December 7, 2009.
39. Moliterno AR, Hexner E, Roboz GJ, et al., An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients, Blood, 2009;114(22):753, ASH Annual Meeting Abstracts, New Orleans, LA, December 7, 2009.
US ONCOLOGY & HEMATOLOGY
63
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84